Recent Updates
Recently added Catalysts
HELP Positive Sentiment

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Friday, August 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Helus Pharma has reported its financial results for the first quarter of fiscal 2027, highlighting key business developments. The company appointed Michael Halstead as Chief Executive Officer, aiming to guide Helus through late-stage development and commercialization. Additionally, Helus completed enrollment in the Phase 3 APPROACH study for its drug HLP003 targeting Major Depressive Disorder.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of an experienced CEO to lead the company.
  • Completion of enrollment in a pivotal Phase 3 study.
  • Focus on Major Depressive Disorder, a significant health issue.

Full Press Release Details

- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization - - Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder (“MDD”); topline

Frequently Asked Questions

Who is the new CEO of Helus Pharma?

Michael Halstead has been appointed as the new CEO of Helus Pharma.

What study did Helus Pharma complete enrollment for?

Helus Pharma completed enrollment in the Phase 3 APPROACH study.

What condition is HLP003 targeting?

HLP003 is targeting Major Depressive Disorder (MDD).

When did Helus Pharma report its financial results?

Helus Pharma reported its financial results for the first quarter of fiscal 2027.

ShareAdd on Google
Tags: HELP Viatris Investor Conferences Healthcare Helus Pharma HLP003 Major Depressive Disorder Michael Halstead Phase 3
Last updated: Aug 14, 2026

Biotech snapshot

Lead asset
CYB003Phase 3
Major Depressive Disorder →